New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill A3974

Introduced
2/27/24  
Refer
2/27/24  
Refer
5/13/24  
Report Pass
6/24/24  
Engrossed
9/26/24  
Refer
9/30/24  
Report Pass
3/3/25  
Refer
3/17/25  
Report Pass
3/17/25  
Engrossed
3/24/25  
Enrolled
6/30/25  
Chaptered
8/11/25  

Caption

Prohibits use of deceptive marketing practices by substance use disorder treatment providers.

Impact

If enacted, A3974 would have a significant impact on state laws governing advertising and marketing practices for substance use treatment services. Under this bill, any violation of the set advertising standards could lead to substantial civil penalties, not exceeding $20,000 per violation. This penalty could be pursued in municipal court, thereby empowering individuals who suffer from misleading practices to seek restitution. The law reflects a growing recognition of the need for regulation within the addiction treatment marketplace to protect vulnerable populations from exploitation.

Summary

Assembly Bill A3974 aims to prohibit deceptive marketing practices employed by substance use disorder treatment providers and recovery residences in New Jersey. The bill intends to ensure that marketing materials are transparent, accurate, and straightforward, providing essential information about the types of services offered, the locations where services are provided, and the treatment providers' contact details. It applies to all treatment providers licensed under relevant state statutes and seeks to enhance consumer protection against misleading advertising in the substance use treatment sector.

Sentiment

The sentiment surrounding A3974 is mostly supportive, reflecting a broader movement towards improving transparency and ethical standards in treatment practices for substance use disorders. Advocates for the bill highlight the necessity of safeguarding individuals seeking help from deceptive practices that could lead to harmful outcomes. There is consensus among stakeholders that clear and accurate information is vital in promoting better patient choices and fostering a trustworthy treatment environment. However, some industry representatives express concerns about the bill potentially imposing excessive regulation that might stifle legitimate marketing efforts.

Contention

Notable points of contention include the balance between regulation and business autonomy within the recovery industry. While proponents argue that regulating marketing practices protects consumers, some treatment providers fear that strict guidelines may hinder their ability to reach potential clients effectively. Additionally, there are concerns about the enforcement mechanisms, as the responsibility for monitoring compliance primarily falls on the state’s health and community affairs departments. The debate encapsulates a critical tension between protecting public health and accommodating business interests within a competitive market.

Companion Bills

NJ S3955

Same As Prohibits use of deceptive marketing practices by substance use disorder treatment providers.

Previously Filed As

NJ S350

Prohibits substance use disorder treatment providers from using deceptive marketing practices.

NJ S2490

Establishes "Substance Use Disorder and Addiction Treatment Best Practices Task Force."

NJ A2599

Establishes "Substance Use Disorder and Addiction Treatment Best Practices Task Force."

NJ HB1367

Involuntary treatment of substance use disorder.

NJ SB0137

Involuntary treatment of substance use disorder.

NJ SB1814

substance use disorder treatment; committee

NJ S2492

Increases access to substance use disorder treatment; Requires Medicaid coverage for substance use disorder services provided by community-based organizations.

NJ A626

Increases access to substance use disorder treatment; Requires Medicaid coverage for substance use disorder services provided by community-based organizations.

NJ S348

Revises law concerning substance use disorder treatment facility patient referrals.

NJ S157

Establishes Office of Alcohol and Drug Use Disorders Policy to oversee, direct, and coordinate resources, funding, and data tracking concerning treatment of substance use disorders.

Similar Bills

CA SB1353

Alcohol or other drug recovery or treatment facilities: residential use of property.

CA AB1882

Safe Delivery Fund Pilot Program.

CA AB3

Alcohol and drug treatment facilities: local regulation.

CA AB1779

Alcoholism and drug abuse recovery and treatment programs: inducement of participants.

CA AB423

Alcoholism or drug abuse recovery or treatment programs and facilities: disclosures.

CA SB1060

Alcohol and drug treatment facilities.

CA SB329

An act to add Section 11834.

CA SB43

Substance use disorder: addiction treatment referral agencies.